Antibody data
- Antibody Data
- Antigen structure
- References [27]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11859-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#11859-1-AP, RRID:AB_2065902
- Product name
- BRD3 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated BRD3 antibody (Cat. #11859-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IF, IHC, IP, WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Tumor suppressive role of the epigenetic master regulator BRD3 in colorectal cancer.
The BET inhibitor GNE-987 effectively induces anti-cancer effects in T-cell acute lymphoblastic leukemia by targeting enhancer regulated genes.
A di-acetyl-decorated chromatin signature couples liquid condensation to suppress DNA end synapsis.
The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage.
BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3.
Targeting BRD3 eradicates nuclear TYRO3-induced colorectal cancer metastasis.
A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells.
The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma.
BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
BRD4 inhibitor MZ1 exerts anti-cancer effects by targeting MYCN and MAPK signaling in neuroblastoma.
BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma.
Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia.
A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues.
An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16.
BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways.
Cancer Selective Target Degradation by Folate-Caged PROTACs.
Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer.
BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.
BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc.
The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer.
Light-induced control of protein destruction by opto-PROTAC.
Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
The acetyllysine reader BRD3R promotes human nuclear reprogramming and regulates mitosis.
microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network.
Hashimoto M, Masuda T, Nakano Y, Tobo T, Saito H, Koike K, Takahashi J, Abe T, Ando Y, Ozato Y, Hosoda K, Higuchi S, Hisamatsu Y, Toshima T, Yonemura Y, Hata T, Uemura M, Eguchi H, Doki Y, Mori M, Mimori K
Cancer science 2024 Jun;115(6):1866-1880
Cancer science 2024 Jun;115(6):1866-1880
The BET inhibitor GNE-987 effectively induces anti-cancer effects in T-cell acute lymphoblastic leukemia by targeting enhancer regulated genes.
Yu J, Yang Y, Zhou R, Tao Y, Zhu F, Jiao W, Zhang Z, Ji T, Li T, Fang F, Xie Y, Wu D, Zhuo R, Li X, Chen Y, Yin H, Wang J, Pan J
Carcinogenesis 2024 Jun 10;45(6):424-435
Carcinogenesis 2024 Jun 10;45(6):424-435
A di-acetyl-decorated chromatin signature couples liquid condensation to suppress DNA end synapsis.
Bao K, Ma Y, Li Y, Shen X, Zhao J, Tian S, Zhang C, Liang C, Zhao Z, Yang Y, Zhang K, Yang N, Meng FL, Hao J, Yang J, Liu T, Yao Z, Ai D, Shi L
Molecular cell 2024 Apr 4;84(7):1206-1223.e15
Molecular cell 2024 Apr 4;84(7):1206-1223.e15
The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage.
Zhu X, Liu W, Tang X, Chen Y, Ge X, Ke Q, Liang X, Gan Y, Zheng Y, Zou M, Deng M, Liu Y, Li DW, Gong L
Journal of neuroinflammation 2023 May 22;20(1):119
Journal of neuroinflammation 2023 May 22;20(1):119
BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting CCND3.
Ma L, Wang J, Yang Y, Lu J, Ling J, Chu X, Zhang Z, Tao Y, Li X, Tian Y, Li Z, Zhang Y, Sang X, Lu L, Wan X, Zhang K, Chen Y, Yu J, Zhuo R, Wu S, Pan J, Zhou X, Hu Y, Hu S
Hematology (Amsterdam, Netherlands) 2023 Dec;28(1):2247253
Hematology (Amsterdam, Netherlands) 2023 Dec;28(1):2247253
Targeting BRD3 eradicates nuclear TYRO3-induced colorectal cancer metastasis.
Hsu PL, Chien CW, Tang YA, Lin BW, Lin SC, Lin YS, Chen SY, Sun HS, Tsai SJ
Science advances 2023 Apr 14;9(15):eade3422
Science advances 2023 Apr 14;9(15):eade3422
A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells.
Zhang K, Gao L, Wang J, Chu X, Zhang Z, Zhang Y, Fang F, Tao Y, Li X, Tian Y, Li Z, Sang X, Ma L, Lu L, Chen Y, Yu J, Zhuo R, Wu S, Pan J, Hu S
Pathology oncology research : POR 2022;28:1610447
Pathology oncology research : POR 2022;28:1610447
The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma.
Jia SQ, Zhuo R, Zhang ZM, Yang Y, Tao YF, Wang JW, Li XL, Xie Y, Li G, Wu D, Chen YL, Yu JJ, Feng CX, Li ZH, Zhou RF, Yang RD, Yang PC, Zhou B, Wan XM, Wu YM, Jiao WY, Zhou NN, Fang F, Pan J
Journal of immunology research 2022;2022:7945884
Journal of immunology research 2022;2022:7945884
BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
Sang X, Zhang Y, Fang F, Gao L, Tao Y, Li X, Zhang Z, Wang J, Tian Y, Li Z, Yao D, Wu Y, Chu X, Zhang K, Ma L, Lu L, Chen Y, Yu J, Zhuo R, Wu S, Zhang Z, Pan J, Hu S
Journal of immunology research 2022;2022:7912484
Journal of immunology research 2022;2022:7912484
BRD4 inhibitor MZ1 exerts anti-cancer effects by targeting MYCN and MAPK signaling in neuroblastoma.
Zhang X, Guo X, Zhuo R, Tao Y, Liang W, Yang R, Chen Y, Cao H, Jia S, Yu J, Liao X, Li X, Fang F, Li G, Wu D, Xu Y, Li Z, Pan J, Wang J
Biochemical and biophysical research communications 2022 May 14;604:63-69
Biochemical and biophysical research communications 2022 May 14;604:63-69
BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma.
Chen YL, Li XL, Li G, Tao YF, Zhuo R, Cao HB, Jiao WY, Li ZH, Zhu ZH, Fang F, Xie Y, Liao XM, Wu D, Wang HR, Yu JJ, Jia SQ, Yang Y, Feng CX, Yang PC, Fei XD, Wang JW, Xu YY, Qian GH, Zhang ZM, Pan J
Cell & bioscience 2022 Mar 18;12(1):33
Cell & bioscience 2022 Mar 18;12(1):33
Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia.
Fang F, Lu J, Sang X, Tao YF, Wang JW, Zhang ZM, Zhang YP, Li XL, Xie Y, Wu SY, Chu XR, Li G, Wu D, Chen YL, Yu JJ, Jia SQ, Feng CX, Tian YY, Li ZH, Ling J, Hu SY, Pan J
Journal of experimental & clinical cancer research : CR 2022 Jul 16;41(1):225
Journal of experimental & clinical cancer research : CR 2022 Jul 16;41(1):225
A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues.
Yamanaka S, Horiuchi Y, Matsuoka S, Kido K, Nishino K, Maeno M, Shibata N, Kosako H, Sawasaki T
Nature communications 2022 Jan 10;13(1):183
Nature communications 2022 Jan 10;13(1):183
An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16.
Ma L, Li G, Yang T, Zhang L, Wang X, Xu X, Ni H
Cancer chemotherapy and pharmacology 2022 Dec;90(6):431-444
Cancer chemotherapy and pharmacology 2022 Dec;90(6):431-444
BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
Ma L, Wang J, Zhang Y, Fang F, Ling J, Chu X, Zhang Z, Tao Y, Li X, Tian Y, Li Z, Sang X, Zhang K, Lu L, Wan X, Chen Y, Yu J, Zhuo R, Wu S, Lu J, Pan J, Hu S
Cancer biology & therapy 2022 Dec 31;23(1):1-15
Cancer biology & therapy 2022 Dec 31;23(1):1-15
ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways.
Liao X, Qian X, Zhang Z, Tao Y, Li Z, Zhang Q, Liang H, Li X, Xie Y, Zhuo R, Chen Y, Jiang Y, Cao H, Niu J, Xue C, Ni J, Pan J, Cui D
Frontiers in oncology 2021;11:753119
Frontiers in oncology 2021;11:753119
Cancer Selective Target Degradation by Folate-Caged PROTACs.
Liu J, Chen H, Liu Y, Shen Y, Meng F, Kaniskan HÜ, Jin J, Wei W
Journal of the American Chemical Society 2021 May 19;143(19):7380-7387
Journal of the American Chemical Society 2021 May 19;143(19):7380-7387
Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer.
Wang W, Tang YA, Xiao Q, Lee WC, Cheng B, Niu Z, Oguz G, Feng M, Lee PL, Li B, Yang ZH, Chen YF, Lan P, Wu XJ, Yu Q
Nature communications 2021 Jul 21;12(1):4441
Nature communications 2021 Jul 21;12(1):4441
BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.
Ni M, Li J, Zhao H, Xu F, Cheng J, Yu M, Ke G, Wu X
Oncogene 2021 Apr;40(15):2711-2724
Oncogene 2021 Apr;40(15):2711-2724
BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
Wu S, Jiang Y, Hong Y, Chu X, Zhang Z, Tao Y, Fan Z, Bai Z, Li X, Chen Y, Li Z, Ding X, Lv H, Du X, Lim SL, Zhang Y, Huang S, Lu J, Pan J, Hu S
Cancer cell international 2021 Apr 22;21(1):230
Cancer cell international 2021 Apr 22;21(1):230
PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc.
Li Z, Lim SL, Tao Y, Li X, Xie Y, Yang C, Zhang Z, Jiang Y, Zhang X, Cao X, Wang H, Qian G, Wu Y, Li M, Fang F, Liu Y, Fu M, Ding X, Zhu Z, Lv H, Lu J, Xiao S, Hu S, Pan J
Frontiers in oncology 2020;10:574525
Frontiers in oncology 2020;10:574525
The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer.
Bian X, Wang X, Zhang Q, Ma L, Cao G, Xu A, Han J, Huang J, Lin W
Frontiers in oncology 2020;10:565820
Frontiers in oncology 2020;10:565820
Light-induced control of protein destruction by opto-PROTAC.
Liu J, Chen H, Ma L, He Z, Wang D, Liu Y, Lin Q, Zhang T, Gray N, Kaniskan HÜ, Jin J, Wei W
Science advances 2020 Feb;6(8):eaay5154
Science advances 2020 Feb;6(8):eaay5154
Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.
Lim SL, Damnernsawad A, Shyamsunder P, Chng WJ, Han BC, Xu L, Pan J, Pravin DP, Alkan S, Tyner JW, Koeffler HP
Haematologica 2019 Jun;104(6):1209-1220
Haematologica 2019 Jun;104(6):1209-1220
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, Chen T, Shimizu K, Beca F, Blattner M, Vasudevan D, Buckley DL, Qi J, Buser L, Liu P, Inuzuka H, Beck AH, Wang L, Wild PJ, Garraway LA, Rubin MA, Barbieri CE, Wong KK, Muthuswamy SK, Huang J, Chen Y, Bradner JE, Wei W
Nature medicine 2017 Sep;23(9):1063-1071
Nature medicine 2017 Sep;23(9):1063-1071
The acetyllysine reader BRD3R promotes human nuclear reprogramming and regulates mitosis.
Shao Z, Zhang R, Khodadadi-Jamayran A, Chen B, Crowley MR, Festok MA, Crossman DK, Townes TM, Hu K
Nature communications 2016 Mar 7;7:10869
Nature communications 2016 Mar 7;7:10869
microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network.
Zhang L, Deng T, Li X, Liu H, Zhou H, Ma J, Wu M, Zhou M, Shen S, Li X, Niu Z, Zhang W, Shi L, Xiang B, Lu J, Wang L, Li D, Tang H, Li G
Carcinogenesis 2010 Apr;31(4):559-66
Carcinogenesis 2010 Apr;31(4):559-66
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- human brain tissue were subjected to SDS PAGE followed by western blot with 11859-1-AP(BRD3 antibody) at dilution of 1:200
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The BRD3 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human BRD3. This antibody recognizes human, mouse, rat antigen. The BRD3 antibody has been validated for the following applications: ELISA, WB, IHC analysis.